These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 35572524)
1. Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures. Li B; Wang F; Wang N; Hou K; Du J Front Immunol; 2022; 13():871564. PubMed ID: 35572524 [TBL] [Abstract][Full Text] [Related]
2. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044 [TBL] [Abstract][Full Text] [Related]
3. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
4. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma. Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424 [TBL] [Abstract][Full Text] [Related]
5. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas. Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988 [No Abstract] [Full Text] [Related]
6. Identification of Critical m Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046 [TBL] [Abstract][Full Text] [Related]
7. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma. Tang G; Peng J; Huo L; Yin W BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314 [TBL] [Abstract][Full Text] [Related]
8. Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response. Ye S; Yang B; Yang L; Wei W; Fu M; Yan Y; Wang B; Li X; Liang C; Zhao W Sci Rep; 2024 Jun; 14(1):14758. PubMed ID: 38926605 [TBL] [Abstract][Full Text] [Related]
9. Multifaceted bioinformatic analysis of m6A-related ferroptosis and its link with gene signatures and tumour-infiltrating immune cells in gliomas. Yang Y; Hao L; Guiyang L; Haozhe P J Cell Mol Med; 2024 Sep; 28(17):e70060. PubMed ID: 39248438 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J Front Immunol; 2021; 12():669750. PubMed ID: 34054840 [TBL] [Abstract][Full Text] [Related]
11. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer. Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H Front Immunol; 2021; 12():769425. PubMed ID: 34804059 [TBL] [Abstract][Full Text] [Related]
13. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364 [TBL] [Abstract][Full Text] [Related]
14. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the m6A/m1A/m5C/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data. Yang L; Huang Z; Deng Y; Zhang X; Lv Z; Huang H; Sun Q; Liu H; Liang H; He B; Hu F J Gene Med; 2024 Feb; 26(2):e3666. PubMed ID: 38391150 [TBL] [Abstract][Full Text] [Related]
16. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment. Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861 [TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma. Xu S; Tang L; Liu Z; Luo C; Cheng Q Front Immunol; 2021; 12():731048. PubMed ID: 34659218 [TBL] [Abstract][Full Text] [Related]
18. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. Lin WW; Ou GY; Zhao WJ J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473 [TBL] [Abstract][Full Text] [Related]
19. Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma. Zhang L; Qu C; Shi C; Wu F; Tang Y; Li Y; Li J; Feng H; Zhong S; Yang J; Zeng X; Peng X PLoS One; 2023; 18(1):e0279119. PubMed ID: 36649311 [TBL] [Abstract][Full Text] [Related]
20. Prognosis Analysis and Validation of m Lin S; Xu H; Zhang A; Ni Y; Xu Y; Meng T; Wang M; Lou M Front Oncol; 2020; 10():541401. PubMed ID: 33123464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]